ECP-DL cell infusion for living donor kidney transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether giving a special type of immune cells from your kidney donor (called ECP-DL cells) can help your body accept the new kidney without strong anti-rejection drugs. It is for people who are getting their first kidney transplant from a donor who is not a perfect genetic match.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 30 and 70 years old and getting your first kidney transplant.
- Your donor must be willing to donate a small blood sample to prepare the special immune cells.
- You and your donor must test negative for certain infections (like HIV, hepatitis, syphilis, West Nile virus, and tuberculosis).
- You cannot have any major health issues like uncontrolled diabetes, severe heart disease, or a recent stroke.
- You and your donor must be willing to use birth control for a year after the procedure.
- You cannot have had a splenectomy (spleen removal), have very high antibodies against donors, or have certain light-sensitive skin conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special solution (iCM012) that is used to wash and preserve kidneys from older deceased donors (ages 55–75) before they are transplanted. The goal is to see if it helps the kidneys work better after transplant.
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
This Phase 2 trial studies a treatment using immune cells made from your living donor, given around the time of kidney transplant. It aims to improve transplant safety and outcomes by adjusting the immune response to the new kidney.
This trial tests a new treatment using your own immune cells, called tolerogenic dendritic cells, to help your body accept a kidney transplant. It is designed for people who are highly sensitized and have a very hard time finding a matching donor kidney.
This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
Hear when a new Kidney Transplant Failure and Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.